Alphatec Holdings (NASDAQ:ATEC) Stock, Quote.Headers.trade-ideas

Alphatec Holdings

Alphatec Holdings Inc is a medical technology company focused on the designing, development, and advancement of products for the surgical treatment of spinal disorders associated with disease and degeneration, congenital deformities, and trauma. The company's spine approach technologies include Posterior Cervical Fusion, Anterior Cervical Discectomy and Fusion, Lateral Interbody Fusion, and Posterior Lumbar Interbody Fusion among others.

Crude-oil-4-logo

Earnings

News

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

ALXO

ATEC

EXAS

MRNA

OMCL

RDHL

Vintage Wine Estates, Inc. - Common Stock

Crude Oil Moves Lower; Moderna Shares Plunge

wall street chart shutter2

Dow Dips Over 500 Points; ISM Manufacturing PMI Falls In July

October,29,,2021,,Brazil.,In,This,Photo,Illustration,The,Meta

BBLG

IMRX

Nasdaq Surges 1%; Meta Posts Upbeat Earnings

Alphatec Holdings Inc

Atec Inc

Lake Street analyst Brooks O'Neil maintains Alphatec Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATEC#NASDAQ">ATEC</a>) with a Buy and lowers the price target from $32 to $18.

Price Target

Analyst Ratings

Lake Street Maintains Buy on Alphatec Holdings, Lowers Price Target to $18

Canaccord Genuity analyst Caitlin Cronin maintains Alphatec Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATEC#NASDAQ">ATEC</a>) with a Buy and maintains $20 price target.

Canaccord Genuity Maintains Buy on Alphatec Holdings, Maintains $20 Price Target

Alphatec Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATEC#NASDAQ">ATEC</a>) has been analyzed by 9 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $18.11, a high estimate of $25.00, and a low estimate of $12.00. Experiencing a 16.85% decline, the current average is now lower than the previous average price target of $21.78. 
<img src="https://www.benzinga.com/files/images/story/2024/1724328044_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Alphatec Holdings. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Saxon</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$13.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Matt O'Brien</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$12.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Mathew Blackman</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$16.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Vik Chopra</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$19.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Sean Lee</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$20.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>David Saxon</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$23.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Caitlin Cronin</td>
<td>Canaccord Genuity</td>
<td>Maintains</td>
<td>Buy</td>
<td>$25.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Drew Ranieri</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$16.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Mathew Blackman</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$19.00</td>
<td>$24.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Alphatec Holdings. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Alphatec Holdings compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Alphatec Holdings's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Alphatec Holdings's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/ATEC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Alphatec Holdings analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>About Alphatec Holdings</h2>
Alphatec Holdings Inc is a medical technology company focused on the designing, development, and advancement of products for the surgical treatment of spinal disorders associated with disease and degeneration, congenital deformities, and trauma. The company's spine approach technologies include Posterior Cervical Fusion, Anterior Cervical Discectomy and Fusion, Lateral Interbody Fusion, and Posterior Lumbar Interbody Fusion among others.
<h3>Key Indicators: Alphatec Holdings's Financial Health</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Alphatec Holdings's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 24.51% as of 30 June, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Alphatec Holdings's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -27.94%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Alphatec Holdings's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -148.84%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -5.27%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: With a high debt-to-equity ratio of 32.47, Alphatec Holdings faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>Analyst Ratings: What Are They?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Where Alphatec Holdings Stands With Analysts

Needham analyst David Saxon maintains Alphatec Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATEC#NASDAQ">ATEC</a>) with a Buy and lowers the price target from $23 to $13.

Needham Maintains Buy on Alphatec Holdings, Lowers Price Target to $13

U.S. stocks traded lower toward the end of trading, with the Dow Jones index dipping more than 650 points on Thursday.
The Dow traded down 1.61% to 40,184.39 while the NASDAQ fell 2.77% to 17,111.79. The S&amp;P 500 also fell, dropping, 1.78% to 5,424.16.
Leading and Lagging Sectors Utilities shares gained by 1.5% on Thursday.
In trading on Thursday, information technology shares fell by 4%.
Top Headline Moderna Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) stock dipped more than 20% on Thursday as the company lowered its 2024 sales guidance due to weaker demand for its COVID-19 vaccines.
Moderna now projects 2024 net sales of between $3 billion and $3.5 billion from its respiratory franchise versus previous guidance of about $4 billion, citing low EU sales in 2024, potential revenue deferrals for certain international sales into 2025, and an increasingly competitive environment for respiratory vaccines in the U.S.
Moderna reported second-quarter revenue of $241 million, compared with $344 million a year earlier, beating the consensus of $132.18 million.
Net loss was $1.28 billion, or $3.33 a share, versus a loss of $1.38 billion, or $3.62 a share, a year earlier, surpassing the consensus of $(3.36).
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>RedHill Biopharma Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDHL#NASDAQ">RDHL</a>) shares shot up 80% to $0.69 after the company announced a new publication showed data demonstrating that triple antimicrobial therapy with RHB-104 plus standard of care, targeting Mycobacterium avium subspecies paratuberculosis, is 64% more effective than SoC alone in Crohn&#8217;s disease.</li>
<li>Shares of Exact Sciences Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) got a boost, surging 23% to $56.26&nbsp;after the company reported better-than-expected second-quarter financial results. Also, the company announced an exclusive license agreement with TwinStrand Biosciences.</li>
<li>Omnicell, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMCL#NASDAQ">OMCL</a>) shares were also up, gaining 31% to $38.20 after the company reported better-than-expected second-quarter financial results and issued FY24 guidance above estimates.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Vintage Wine Estates, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VWE#NASDAQ">VWE</a>) shares dropped 41% to $0.0305 after the company announced a bankruptcy filing and a voluntary delisting and SEC deregistration.</li>
<li>Shares of ALX Oncology Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALXO#NASDAQ">ALXO</a>) were down 40% to $2.89. The company released topline data from its Phase 2 ASPEN-06 clinical trial.</li>
<li>Alphatec Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATEC#NASDAQ">ATEC</a>) was down, falling 29% to $7.15 after the company reported mixed second-quarter financial results.</li>
</ul>
Commodities In commodity news, oil traded down 1.8% to $76.53 while gold traded up 0.3% at $2,481.50.
Silver traded down 1.9% to $28.395 on Thursday, while copper fell 2.8% to $4.0595.
Euro zone
European shares were lower today. The eurozone's STOXX 600 fell 1.23%, Germany's DAX fell 2.30% and France's CAC 40 fell 2.14%. Spain's IBEX 35 Index fell 1.9%, while London's FTSE 100 fell 1.01%.
Asia Pacific Markets
Asian markets closed mixed on Thursday, with Japan's Nikkei 225 dipping 2.49%, Hong Kong's Hang Seng Index falling 0.23% and S&amp;P BSE Sensex gaining 0.15%.
Economics
<ul>
<li>The ISM manufacturing PMI declined to 46.6 in July versus 48.5 in the prior month, below market estimates of 48.8.</li>
<li>Construction spending declined by 0.3% month-over-month to an annual rate of $2,148 billion in June.</li>
<li>U.S. initial jobless claims by 14,000 to 249,000 in the week ending July 27th, beating market estimates of 236,000.</li>
<li>Nonfarm business sector labor productivity increased by 2.3% in the second quarter, compared to a revised 0.4% rise in the prior period.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/08/40101200/top-3-health-care-stocks-that-are-set-to-fly-this-quarter">Top 3 Health Care Stocks That Are Set To Fly This Quarter</a></li>
</ul>

U.S. stocks traded lower midway through trading, with the Dow Jones index dipping more than 500 points on Thursday.
The Dow traded down 1.26% to 40,327.48 while the NASDAQ fell 1.57% to 17,322.26. The S&amp;P 500 also fell, dropping, 1.05% to 5,464.56.
Leading and Lagging Sectors Communication services shares gained by 1.1% on Thursday.
In trading on Thursday, information technology shares fell by 2.3%.
Top Headline The ISM manufacturing PMI declined to 46.6 in July versus 48.5 in the prior month, below market estimates of 48.8.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>RedHill Biopharma Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDHL#NASDAQ">RDHL</a>) shares shot up 56% to $0.6008 after the company announced a new publication showed data demonstrating that triple antimicrobial therapy with RHB-104 plus standard of care, targeting Mycobacterium avium subspecies paratuberculosis, is 64% more effective than SoC alone in Crohn&#8217;s disease.</li>
<li>Shares of Exact Sciences Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) got a boost, surging 24% to $56.70&nbsp;after the company reported better-than-expected second-quarter financial results. Also, the company announced an exclusive license agreement with TwinStrand Biosciences.</li>
<li>Omnicell, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMCL#NASDAQ">OMCL</a>) shares were also up, gaining 28% to $37.29 after the company reported better-than-expected second-quarter financial results and issued FY24 guidance above estimates.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Vintage Wine Estates, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VWE#NASDAQ">VWE</a>) shares dropped 34% to $0.0342 after the company announced a bankruptcy filing and a voluntary delisting and SEC deregistration.</li>
<li>Shares of ALX Oncology Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALXO#NASDAQ">ALXO</a>) were down 37% to $3.0250. The company released topline data from its Phase 2 ASPEN-06 clinical trial.</li>
<li>Alphatec Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATEC#NASDAQ">ATEC</a>) was down, falling 23% to $7.80 after the company reported mixed second-quarter financial results.</li>
</ul>
Commodities In commodity news, oil traded down 0.8% to $77.26 while gold traded up 0.7% at $2,489.90.
Silver traded down 1% to $28.655 on Thursday, while copper fell 1.9% to $4.0975.
Euro zone
European shares were lower today. The eurozone's STOXX 600 fell 1.23%, Germany's DAX fell 2.32% and France's CAC 40 fell 2.14%. Spain's IBEX 35 Index fell 1.9%, while London's FTSE 100 fell 1.01%.
Asia Pacific Markets
Asian markets closed mixed on Thursday, with Japan's Nikkei 225 dipping 2.49%, Hong Kong's Hang Seng Index falling 0.23% and S&amp;P BSE Sensex gaining 0.15%.
Economics
<ul>
<li>The ISM manufacturing PMI declined to 46.6 in July versus 48.5 in the prior month, below market estimates of 48.8.</li>
<li>Construction spending declined by 0.3% month-over-month to an annual rate of $2,148 billion in June.</li>
<li>U.S. initial jobless claims by 14,000 to 249,000 in the week ending July 27th, beating market estimates of 236,000.</li>
<li>Nonfarm business sector labor productivity increased by 2.3% in the second quarter, compared to a revised 0.4% rise in the prior period.</li>
</ul>
Now Read This:<a href="https://www.benzinga.com/trading-ideas/long-ideas/24/08/40101200/top-3-health-care-stocks-that-are-set-to-fly-this-quarter"> </a>
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/08/40101200/top-3-health-care-stocks-that-are-set-to-fly-this-quarter">Top 3 Health Care Stocks That Are Set To Fly This Quarter</a></li>
</ul>

Piper Sandler analyst Matt O'Brien maintains Alphatec Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATEC#NASDAQ">ATEC</a>) with a Overweight and lowers the price target from $17 to $12.

Piper Sandler Maintains Overweight on Alphatec Holdings, Lowers Price Target to $12

Stifel analyst Mathew Blackman maintains Alphatec Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATEC#NASDAQ">ATEC</a>) with a Buy and lowers the price target from $19 to $16.

Stifel Maintains Buy on Alphatec Holdings, Lowers Price Target to $16

U.S. stocks traded mostly higher this morning, with the Nasdaq Composite gaining around 1% on Thursday.
The Dow traded up 0.03% to 40,853.73 while the NASDAQ rose 0.96% to 17,768.43. The S&amp;P 500 also rose, gaining, 0.62% to 5,556.62.
Leading and Lagging Sectors Communication services shares jumped by 3.4% on Thursday.
In trading on Thursday, energy shares fell by 0.8%.
Top Headline Meta Platforms, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) reported better-than-expected second-quarter financial results and issued strong third-quarter guidance.
Meta reported second-quarter revenue of $39.07 billion, beating analyst estimates of $38.31 billion. The company reported second-quarter adjusted earnings of $5.16 per share, beating analyst estimates of $4.73 per share.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>RedHill Biopharma Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDHL#NASDAQ">RDHL</a>) shares shot up 69% to $0.6499 after the company announced a new publication showed data demonstrating that triple antimicrobial therapy with RHB-104 plus standard of care, targeting Mycobacterium avium subspecies paratuberculosis, is 64% more effective than SoC alone in Crohn&#8217;s disease.</li>
<li>Shares of Bone Biologics Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBLG#NASDAQ">BBLG</a>) got a boost, surging 52% to $3.2897&nbsp;after gaining 23% on Wednesday.</li>
<li>Immuneering Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMRX#NASDAQ">IMRX</a>) shares were also up, gaining 38% to $1.555 after the company announced that IMM-1-104 was granted Fast Track designation from the FDA.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Vintage Wine Estates, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VWE#NASDAQ">VWE</a>) shares dropped 38% to $0.0323 after the company announced a bankruptcy filing and a voluntary delisting and SEC deregistration.</li>
<li>Shares of ALX Oncology Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALXO#NASDAQ">ALXO</a>) were down 32% to $3.25. The company released topline data from its Phase 2 ASPEN-06 clinical trial.</li>
<li>Alphatec Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATEC#NASDAQ">ATEC</a>) was down, falling 31% to $7.01 after the company reported mixed second-quarter financial results.</li>
</ul>
Commodities In commodity news, oil traded up 0.6% to $78.37 while gold traded up 1% at $2,497.80.
Silver traded up 0.7% to $29.125 on Thursday, while copper fell 0.5% to $4.1545.
Euro zone
European shares were mostly lower today. The eurozone's STOXX 600 fell 0.2%, Germany's DAX fell 1.1% and France's CAC 40 fell 1.3%. Spain's IBEX 35 Index fell 0.7%, while London's FTSE 100 rose 0.2%.
Asia Pacific Markets
Asian markets closed mixed on Thursday, with Japan's Nikkei 225 dipping 2.49%, Hong Kong's Hang Seng Index falling 0.23% and S&amp;P BSE Sensex gaining 0.15%.
Economics
<ul>
<li>The ISM manufacturing PMI declined to 46.6 in July versus 48.5 in the prior month, below market estimates of 48.8.</li>
<li>Construction spending declined by 0.3% month-over-month to an annual rate of $2,148 billion in June.</li>
<li>U.S. initial jobless claims by 14,000 to 249,000 in the week ending July 27th, beating market estimates of 236,000.</li>
<li>Nonfarm business sector labor productivity increased by 2.3% in the second quarter, compared to a revised 0.4% rise in the prior period.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/08/40101200/top-3-health-care-stocks-that-are-set-to-fly-this-quarter">Top 3 Health Care Stocks That Are Set To Fly This Quarter</a></li>
</ul>

Wells Fargo analyst Vik Chopra maintains Alphatec Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATEC#NASDAQ">ATEC</a>) with a Overweight and lowers the price target from $26 to $19.

Wells Fargo Maintains Overweight on Alphatec Holdings, Lowers Price Target to $19

HC Wainwright &amp; Co. analyst Sean Lee reiterates Alphatec Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATEC#NASDAQ">ATEC</a>) with a Buy and maintains $20 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on Alphatec Holdings, Maintains $20 Price Target

Shares of Carvana Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVNA#NYSE">CVNA</a>) rose sharply in today's pre-market trading after the company reported better-than-expected <a href="https://www.benzinga.com/news/24/07/40082489/carvana-q2-earnings-revenue-beat-eps-beat-vehicle-sales-jump-33-upbeat-guidance-and-more">second-quarter financial results</a>.
Carvana reported second-quarter revenue of $3.41 billion, beating the consensus estimate of $3.244 billion, according to Benzinga Pro. The used car retailer reported quarterly earnings of 14 cents per share, beating analyst estimates for a loss of 12 cents per share.
Carvana shares jumped 13.4% to $151.12 in pre-market trading.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>FSD Pharma Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUGE#NASDAQ">HUGE</a>) gained 55.2% to $0.1568 in pre-market trading after falling 7% on Wednesday.</li>
<li>Immuneering Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMRX#NASDAQ">IMRX</a>) gained 37.2% to $1.55 in pre-market trading after the company announced that IMM-1-104 was granted Fast Track designation from the FDA.</li>
<li>CareDx, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>) rose 23% to $24.58 in today's pre-market trading after the company reported better-than-expected second-quarter financial results.</li>
<li>MediaAlpha, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAX#NYSE">MAX</a>) jumped 22.1% to $17.91 in pre-market trading after the company reported better-than-expected second-quarter financial results.</li>
<li>Bone Biologics Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBLG#NASDAQ">BBLG</a>) shares gained 20.8% to $2.61 in pre-market trading after gaining 23% on Wednesday.</li>
<li>Olo Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OLO#NYSE">OLO</a>) shares gained 19.1% to $5.69 in pre-market trading after the company reported better-than-expected second-quarter sales results.</li>
<li>Sunnova Energy International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOVA#NYSE">NOVA</a>) shares rose 17.5% to $8.31 in pre-market trading following upbeat quarterly results.</li>
<li>Kaixin Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KXIN#NASDAQ">KXIN</a>) shares gained 17.5% to $0.1308 in pre-market trading after the company announced it received a non-compliance notification from the Nasdaq.</li>
<li>Rush Street Interactive, Inc. (NYSE RSI) shares rose 16.8% to $11.69 in pre-market trading after the company reported better-than-expected second-quarter earnings and raised FY24 revenue forecast.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>ALX Oncology Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALXO#NASDAQ">ALXO</a>) shares dipped 25.8% to $3.56 in pre-market trading. The company announced it will host an investor call and webcast to share topline data results from the Phase 2 ASPEN-06 clinical trial evaluating evorpacept for the treatment of advanced HER2-positive gastric cancer.</li>
<li>noco-noco Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNC#NASDAQ">NCNC</a>) shares fell 21.9% to $0.2240 in pre-market trading after jumping 88% on Wednesday.</li>
<li>Alphatec Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATEC#NASDAQ">ATEC</a>) shares declined 18.9% to $8.19 in pre-market trading after the company reported second-quarter results.</li>
<li>Udemy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UDMY#NASDAQ">UDMY</a>) fell 16.7% to $7.70 pre-market trading after the company reported mixed second-quarter financial results.</li>
<li>Teladoc Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) shares declined 16.3% to $7.89 in pre-market trading following weak quarterly sales results.</li>
<li>Tenable Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TENB#NASDAQ">TENB</a>) shares fell 14% to $39.51 in pre-market trading after the company reported second-quarter financial results.</li>
<li>Standard Biotools Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LAB#NASDAQ">LAB</a>) dipped 12.9% to $1.95 in pre-market trading after the company posted weak second-quarter results.</li>
<li>Confluent, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CFLT#NASDAQ">CFLT</a>) shares declined 11.1% to $22.24 in pre-market trading after the company reported second-quarter financial results and issued third-quarter EPS guidance below estimates.</li>
<li>Arm Holdings plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>) shares fell 9.6% to $130.28 in pre-market trading following weak second-quarter guidance.</li>
<li>Western Digital Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDC#NASDAQ">WDC</a>) fell 6.3% to $ 62.81 in today's pre-market trading after the company reported its fourth-quarter financial results.</li>
</ul>
Now Read This:
<ul>
<li> <a href="https://www.benzinga.com/markets/24/07/40067769/wall-streets-most-accurate-analysts-weigh-in-on-3-industrials-stocks-with-over-4-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Weigh In On 3 Industrials Stocks With Over 4% Dividend Yields</a></li>
</ul>

Pre-Market Outlook

Movers

CDNA

CFLT

CVNA

MASSIVE INTERACTIVE NV by Massive Interactive, Inc.

HUGE

KXIN

NCNC

NOVA

TDOC

TENB

UDMY

Why Carvana Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket

WIIM

Alphatec Holdings shares are trading lower after the company reported mixed Q2 finanical results.

Needham analyst David Saxon reiterates Alphatec Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATEC#NASDAQ">ATEC</a>) with a Buy and maintains $23 price target.

Needham Reiterates Buy on Alphatec Holdings, Maintains $23 Price Target

U.S. stock futures were mixed this morning, with the Dow futures falling around 0.1% on Thursday.
Shares of Western Digital Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDC#NASDAQ">WDC</a>) fell in today's pre-market trading after the company reported its <a href="https://www.benzinga.com/news/earnings/24/07/40083943/western-digital-reports-strong-q4-results-guides-q1-above-estimates">fourth-quarter financial results</a>.
Western Digital reported quarterly earnings of $1.44 per share, which beat the analyst consensus estimate of $1.18 by 22.03%. The company reported quarterly sales of $3.76 billion, which beat the analyst consensus estimate of $3.747 billion and is a 40.72% increase over sales of $2.672 billion from the same period last year.
Western Digital shares fell 6.5% to $62.67 in pre-market trading.
Here are some big stocks recording losses in today's pre-market trading session.
<ul>
<li>Alphatec Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATEC#NASDAQ">ATEC</a>) shares declined 18.9% to $8.19 in pre-market trading after the company reported second-quarter results.</li>
<li>Udemy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UDMY#NASDAQ">UDMY</a>) fell 16.7% to $7.70 pre-market trading after the company reported mixed second-quarter financial results.</li>
<li>Teladoc Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) shares declined 16.3% to $7.89 in pre-market trading following weak quarterly sales results.</li>
<li>Tenable Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TENB#NASDAQ">TENB</a>) shares fell 14% to $39.51 in pre-market trading after the company reported second-quarter financial results.</li>
<li>Standard Biotools Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LAB#NASDAQ">LAB</a>) dipped 12.9% to $1.95 in pre-market trading after the company posted weak second-quarter results.</li>
<li>Confluent, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CFLT#NASDAQ">CFLT</a>) shares declined 11.1% to $22.24 in pre-market trading after the company reported second-quarter financial results and issued third-quarter EPS guidance below estimates.</li>
<li>Arm Holdings plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>) shares fell 9.6% to $130.28 in pre-market trading following weak second-quarter guidance.</li>
<li>HSBC Holdings plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HSBC#NYSE">HSBC</a>) fell 4.7% to $43.02 in pre-market trading.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/07/40067769/wall-streets-most-accurate-analysts-weigh-in-on-3-industrials-stocks-with-over-4-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Weigh In On 3 Industrials Stocks With Over 4% Dividend Yields</a></li>
</ul>

HSBC

Western Digital, Udemy, Teladoc Health And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

Guidance

Alphatec Holdings Sees FY24 Revenue Growth 25%

Alphatec Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATEC#NASDAQ">ATEC</a>) reported quarterly losses of $(0.29) per share which missed the analyst consensus estimate of $(0.25) by 16 percent. The company reported quarterly sales of $145.573 million which beat the analyst consensus estimate of $144.491 million by 0.75 percent. This is a 24.51 percent increase over sales of $116.920 million the same period last year.

Earnings Beats

Earnings Misses

Alphatec Holdings Q2 2024 GAAP EPS $(0.29) Misses $(0.25) Estimate, Sales $145.573M Beat $144.491M Estimate

Canaccord Genuity analyst Caitlin Cronin maintains Alphatec Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATEC#NASDAQ">ATEC</a>) with a Buy and maintains $25 price target.

Canaccord Genuity Maintains Buy on Alphatec Holdings, Maintains $25 Price Target

Alphatec Holdings Launches EOS Insight Spine Surgery Platform

Across the recent three months, 4 analysts have shared their insights on Alphatec Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATEC#NASDAQ">ATEC</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Alphatec Holdings, presenting an average target of $18.75, a high estimate of $23.00, and a low estimate of $16.00. This current average represents a 11.76% decrease from the previous average price target of $21.25. 
<img src="https://www.benzinga.com/files/images/story/2024/1721062877_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The analysis of recent analyst actions sheds light on the perception of Alphatec Holdings by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Drew Ranieri</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$16.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Mathew Blackman</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$19.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>David Saxon</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$23.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Matthew O'Brien</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$17.00</td>
<td>$19.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Alphatec Holdings. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Alphatec Holdings compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Alphatec Holdings's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Alphatec Holdings's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/ATEC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Alphatec Holdings analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>All You Need to Know About Alphatec Holdings</h2>
Alphatec Holdings Inc is a medical technology company focused on the designing, development, and advancement of products for the surgical treatment of spinal disorders associated with disease and degeneration, congenital deformities, and trauma. The company's spine approach technologies include Posterior Cervical Fusion, Anterior Cervical Discectomy and Fusion, Lateral Interbody Fusion, and Posterior Lumbar Interbody Fusion among others.
<h3>Understanding the Numbers: Alphatec Holdings's Finances</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Positive Revenue Trend: Examining Alphatec Holdings's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 26.91% as of 31 March, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Alphatec Holdings's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -35.02%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Alphatec Holdings's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -83.85%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Alphatec Holdings's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -6.14%, the company may face hurdles in achieving optimal financial returns.
Debt Management: With a high debt-to-equity ratio of 14.4, Alphatec Holdings faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>The Significance of Analyst Ratings Explained</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

4 Analysts Have This To Say About Alphatec Holdings

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Ayr Wellness (AYRWF – Research Report), Alphatec Holdings (ATEC –...

Analysts Offer Insights on Healthcare Companies: Ayr Wellness (OtherAYRWF), Alphatec Holdings (ATEC) and Neurocrine (NBIX)

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Nuvalent (NUVL – Research Report) and Alphatec Holdi...

Analysts Offer Insights on Healthcare Companies: Nuvalent (NUVL) and Alphatec Holdings (ATEC)

Which stocks are best to buy now? According to Top Wall Street Analysts, the three stocks listed below are Strong Buys. Each stock received a new B...

3 Best Stocks to Buy Now, 8/2/2024, According to Top Analysts

Alphatec: Creating Some Real Back Pain For Its Shareholders

J&J, Stryker among potential suitors for Nevro: Wolfe

Alphatec Holdings (ATEC – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst David Saxon from N...

Alphatec Holdings' Journey to Free Cash Flow Breakeven by 2025: A Cautiously Optimistic Buy Rating Amid Market Skepticism

Lake Street Sticks to Their Buy Rating for Alphatec Holdings (ATEC)

Drew Ranieri, an analyst from Morgan Stanley, maintained the Hold rating on Alphatec Holdings (ATEC – Research Report). The associated price target...

Steady Outlook with Cautious Stance: Hold Rating on Alphatec Holdings

Alphatec Holdings (ATEC – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Vik Chopra fro...

Top Stock Ideas Sent Daily — Join and Gain Your Edge

Top Stock Ideas Sent Daily — Join and Gain Your Edge

Comments

Alphatec Holdings

Alphatec Holdings (ATEC) Forecast

Alphatec Holdings (NASDAQ:ATEC) Stock, Quote.Headers.trade-ideas